Ophthalmology, Retina & Eye Surgery Center Platform Architecture
Integrate clinical optometry feeder networks with high-volume cataract surgical suites, manage multi-million dollar anti-VEGF Buy-and-Bill pharmaceutical working capital, and command premium PE platform valuations.
Ophthalmology and surgical retina represent elite investment targets in outpatient healthcare due to non-discretionary patient demand driven by demographic aging (cataracts, wet macular degeneration, diabetic retinopathy). However, acquiring ophthalmic groups requires managing extreme capital intensity: medical retina practices purchase millions in monthly biologic anti-VEGF injections (Eylea, Vabysmo), while surgical practices rely heavily on Ambulatory Surgery Center (ASC) facility fee cash flows. Kompanie LLP structures integrated eye care MSOs: building symbiotic optometry-to-ophthalmology referral channels, optimizing cash-pay premium toric/multifocal IOL packages, and securing Buy-and-Bill lines of credit.
Deliverables
- Structuring integrated Optometry (OD) and Ophthalmology (MD) co-management protocols compliant with AKS safe harbors.
- Surgical Eye ASC syndication models compliant with OIG 1/3 procedure tests.
- Wholesale anti-VEGF pharmaceutical procurement optimization and specialty pharmacy distribution agreements.
- Premium intraocular lens (IOL) and refractive cash-pay price packaging compliant with CMS guidelines.
Frequently asked questions
Why do ophthalmology platforms command higher valuation multiples than standard primary care?
Ophthalmology platforms generate diversified, high-margin cash streams across clinical encounters, in-office retina injections, surgical ASC facility fees, optical dispensaries, and out-of-pocket elective cash upgrades (premium IOLs and laser cataract surgery).
How does an MSO ensure compliant OD-to-MD patient referrals under the Anti-Kickback Statute?
Optometric co-management arrangements must be based on documented clinical necessity and standardized patient consent, with optometrists reimbursed strictly for verifiable post-operative care (typically 20% of the global surgical fee schedule) without referral remuneration.